Transcription of Heterologous booster COVID-19 vaccination
{{id}} {{{paragraph}}}
Example: quiz answers
Heterologous booster COVID-19 vaccination
Official address Domenico Scarlattilaan 6 1083 HS Amsterdam The Netherlands An agency of the European Union Address for visits and deliveries Refer to Send us a question Go to Telephone +31 (0)88 781 6000 European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 13 December 2021 EMA/349565/2021 Biological Health Threats and Vaccine Strategy Office EMA Pandemic Task Force for COVID-19 (COVID-ETF) Heterologous primary and booster COVID-19 vaccination Evidence based regulatory considerations the spring of 20211, a number of European Union (EU) Member States (MSs) started to apply a strategy of Heterologous primary vaccination , with at least 11 EU MSs vaccinating with a first dose of Vaxzevria followed by a second dose of Comirnaty due to uncertainties related to the risk of Thrombosis with thrombocytopenia syndrome (TTS) following Vaxzevria.
Heterologous primary and booster COVID-19 vaccination Evidence based regulatory considerations 1. Introduction During the spring of 20211, a number of European Union (EU) Member States (MSs) started to apply a strategy of heterologous primary vaccination, with at least 11 EU MSs vaccinating with a first dose of
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: